Its the world's largest producer of insulin and diabetes treatments.
Danish pharma and diabetes drug giant Novo Nordisk is joining a nascent biopharma industry movement to voluntarily limit its hikes on prescription drug prices.
“We recognize that people with diabetes are finding it harder to pay for their healthcare, including the medicines we make,” wrote Novo's U.S. president Jakob Riis in a statement on the company's website. “As a company focused on improving the lives of people with diabetes, this is not acceptable.”
